Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

176.96 -1.17 (-0.66%)
Official Closing Price Updated: 7:00 PM EDT, Sep 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Want to Generate at Least $1,000 in Passive Income Per Year? Invest $26,000 in This Dividend King Stock.
Via The Motley Fool
Topics Retirement
Should You Buy Johnson & Johnson Stock Before July 16th?
Via The Motley Fool
Topics Government World Trade
These 3 Undervalued Stocks Could Surge as Value Rotation Nears
A rotation back into value stocks may be imminent in today's market, giving investors a chance to expose themselves into a catch up play. 
Via MarketBeat
Topics ETFs Economy
Andrew Hill Dumps 38,000 Johnson & Johnson Shares in Q2 2025 Exit
Via The Motley Fool
Topics Regulatory Compliance
P/E Ratio Insights for Johnson & Johnson
 
Via Benzinga
Kenvue CEO Thibaut Mongon Steps Down, Director Kirk Perry To Take On Interim CEO Role
Perry has previously worked with Circana, Google, and was with Procter and Gamble for 23 years. 
Via Stocktwits
Topics Government Stocks
This Stock Has Increased 4,720%: Here's Why It's Still a Buy
Via The Motley Fool
5 of the Best Stocks to Buy in July
These stocks are ready to pop higher. 
Via The Motley Fool
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
Via Benzinga
Topics Government World Trade
The Best High Yield Medical Device Stock to Invest $1,000 in Right Now
Via The Motley Fool
What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill
A steady dose of quality companies will keep your portfolio growing big and strong. 
Via The Motley Fool
Topics Intellectual Property
Johnson & Johnson Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
 
Via Benzinga
2 Dividend Stocks to Double Up on Right Now
Via The Motley Fool
Forecasting The Future: 8 Analyst Projections For Johnson & Johnson
 
Via Benzinga
Option Wheel Strategy: How to Earn Monthly Income Trading Options
The search for consistent, predictable income is a constant for investors in both bull and bear markets. While traditional dividend stocks and bonds are reliable tools, a lesser-known but increasingly... 
Via MarketMinute
Topics Bonds Retirement
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property
Johnson & Johnson's Outlook Clouded By $2 Billion Headwind
Johnson & Johnson's 2025 outlook sees slight EPS and revenue upgrades, while headwinds from biosimilars and tariffs are expected to weigh on performance. 
Via Benzinga
Topics World Trade
Johnson & Johnson (NYSE:JNJ) – A Reliable Dividend Stock Worth Considering
Johnson & Johnson (NYSE:JNJ) offers a reliable 3.33% dividend yield with strong profitability and financial health, making it a solid pick for dividend investors. 
Via Chartmill
Trump Threatens 200% Tariffs On Drug Imports, Says Big Pharma Will Get Some Time 'To Get Their Act Together'
Pharmaceutical investors are being cautious, with concerns over potential supply disruptions, cost pressures, and uncertainty regarding policy implementation. 
Via Stocktwits
Topics ETFs Economy Government
Johnson & Johnson Submits Supplemental Drug Application To FDA For Schizophrenia Drug Caplyta
J&J gained access to Caplyta by the acquisition of Intra-Cellular Therapies, Inc., which was completed in April. 
Via Stocktwits
Topics Government
FDA Issues Early Alert For Johnson & Johnson's Abiomed Heart Pump Controllers
FDA issued an Early Alert for Abiomed's Automated Impella Controllers due to potential safety concerns following reports of 3 deaths. 
Via Benzinga
Should You Forget Johnson & Johnson and Buy This Magnificent High-Yield Dividend Stock Instead?
Via The Motley Fool
Trump's 'Big, Beautiful Bill' Hands $5 Billion Win To Big Pharma: Report
Trump's $3.3 trillion domestic agenda bill, passed by the House on Thursday, includes a significant victory for pharmaceutical companies . 
Via Benzinga
Topics Government
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Dogs Of The Dow: How You Can Get Dividend Stocks With Yields Up To 6.3%
The Dow Jones Industrial Average stocks average a 2% dividend yield through the first six months of 2025. Here are the top yields. 
Via Benzinga
Topics Stocks
Johnson & Johnson's Drug Discount Plan Gets Thrown Out In Court
A federal court denied Johnson & Johnson's motion to implement a 340B drug rebate model, siding with HHS and hospitals who argued it violated program intent. 
Via Benzinga
HDV Is a Popular Dividend ETF for Passive Income. But Is It the Best?
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
FDA Flags Weight Loss Risk In ADHD Meds For Kids — J&J, Novartis Escape New Warning
The updated label applies to extended-release stimulants prescribed off-label to children under six, following data showing higher drug exposure and side effect rates in that age group. 
Via Stocktwits
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment. 
Via Benzinga
Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It.
Via The Motley Fool
Topics Lawsuit Supply Chain
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.